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Health literacy is the skill (social and cognitive) that determines the motivation 
and ability of the person to receive, understand and use information in order 
to improve and maintain good health. Communication between patients and 
pharmacist is essential for optimal patient safety.Objectives: To highlight the 
importance and present the results of conducted research and to give recom-
mendations for improving the health literacy among patients and pharmacists’ 
communication skills. MethOds: The study was conducted in June 2013 in 5 
selected branches of pharmacy-chain “Zdravlje Pharm” in Bijeljina, Republic of 
Srpska, Bosnia and Herzegovina. The sample consisted of 219 patients selected 
randomly, of whom 195 accepted the survey, and 24 rejected to participate. The 
instrument was previously validated and adjusted questionnaire of Pharmacy 
Zrenjanin, Serbia, related to patient satisfaction with pharmacy services, but 
also conceived needs of the thesis, with 32 close-type questions, except one. 
Health literacy of patients and communication with pharmacists were fol-
lowed. The analysis was done in Excel, and the results are given in tables and 
graphs. Results: About 90% of patients reported that pharmacists give clear 
information during consultations and the advices helped them. A total of 65% 
reported to easily remember the information from the pharmacists, which shows 
a good level of patient health literacy; but the rest can have uncertain outcomes 
of the therapy and be exposed to greater safety risks. cOnclusiOns: There is a 
place for improvement of aspects which can contribute to better patient safety. 
That can be achieved by applying certification standards throughout the health 
care system in the Republic of Srpska.
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Objectives: The health care sector is widely regarded as a defensive play in the 
stock market. We analyzed the performance of a pharmaceutical and a biotechnol-
ogy index from March 2000 through April 2013 alongside the S&P 500. MethOds: 
We categorized the S&P 500 from March 2000 through April 2013 into bull and bear 
markets. During this time there were three bull markets and three bear markets. 
Bull and bear markets were defined as changes in the S&P 500 of more than 20%. 
We followed the AMEX Pharmaceutical (^DRG) and Biotechnology (^BTK) Indices to 
represent their sectors. We compared the returns of the sectors with the overall mar-
ket and also calculated their correlated volatility (beta) with the S&P 500. Results: 
For the entire analysis period, the S&P 500 returned 4.59% while ^DRG and ^BTK 
returned 25.43% and 252.83%, respectively. During the bear markets, the S&P 500 
lost at an average annual rate of 27.17%, while ^DRG and ^BTK lost at annual rates 
of 12.16% and 21.99%, respectively. Though ^DRG performed best during the bear 
markets, it was a laggard in the bull market gaining 8.15% annually, while the S&P 
500 and ^ BTK had 22.04% and 31.97% annual returns, respectively. The overall beta 
during our analysis period was 0.63 for ^DRG and 1.07 for ^BTK. cOnclusiOns: 
Both the AMEX Pharmaceutical and Biotechnology Indices fell at a lesser rate than 
the S&P 500 during bear markets. The Pharmaceutical Index may be the more defen-
sive play as it lost at an average annual rate of more than two times less than the 
S&P 500. However, the Biotechnology Index gained almost four times more than the 
Pharmaceutical Index in bull markets and also outperformed the S&P 500 by almost 
10 percentage points during bull markets.
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Objectives: Diagnosis Related Groups (DRG) based methods was introduced for 
acute hospital care reimbursement in 1993 in Hungary (H-DRG) and in 2003 in 
Germany (G-DRG). The aim of our study is to compare the development of DRG 
base rate in Germany and Hungary. MethOds: The Hungarian data derive from the 
financial database of the Hungarian National Health Insurance Fund Administration 
(NHIFA), the only health care financing agency in Hungary. German data derive 
from German DRG Institute. We analyzed how the uniform, nationwide DRG base 
rate has been introduced in both countries. Results: The German DRG system 
consists of 1200 disease groups, while the Hungarian contains ca. 736 groups. The 
German DRG base rate was hospital specific between 2003-2004. From 2005 to 2009 
hospital-specific base rates converged to a state-wide base rate. From 2010 to 2014, 
the state-wide base rates should converge to a nationwide base rate. The German 
hospital specific base rate varied between EUR2200-3200. In Hungary, a hospital 
groups specific base rate was applied for 16 groups of hospitals between 1993-
1998 with a gradual converge of base rates. Middle level (county or regional) base 
rate was not introduced in Hungary. The nationwide uniform DRG base rate was 
set up in 1998 in Hungary. The Hungarian uniform DRG base rate was EUR518 in 
2012. cOnclusiOns: Both Hungary and Germany applied a gradual implementa-
tion of uniform DRG base rate. Germany took three steps (hospital, Lander and 
nationwide), while Hungary took two steps (hospital group, nationwide) in reaching 
the nationwide uniform DRG base rate.
Objectives: Turkish health care system has developed in terms of quality, access, 
equity and efficiency with the introduction of a number of reforms under “Health 
Transformation Program” since 2003. However, these have created significant 
financial burden to the government. In order to contain expenditures, avoid over-
use, misuse and abuse; government has implemented certain cost sharing tools. 
Our objective is to define how co-payment mechanism has affected patients’ 
purchasing behavior regarding OTC-type products. MethOds: Regulations and 
reports published by Ministry of Health and Social Security Institution, “Health 
Systems in Transition Turkey 2011” and “IMS Market Prognosis 2012-2016” reports 
are examined. Results: In Turkey, family physicians do not act like gatekeepers 
since a formal referral system does not exist. Therefore, patients could directly 
apply to secondary/tertiary health care services without co-pay. At secondary/
tertiary health care levels, co-payment rate is 5 TL and 12 TL for outpatient care 
in public and private hospitals respectively, 3 TL for prescription fee and extra 
1 TL for each product exceeding 3 products per prescription. All active workers 
pay 20% while retirees pay 10% of total amount of the prescriptions as co-pay. 
Patients with chronic conditions requiring medical report are exempt from co-
pay. Considering different co-payment rates and number of visits/prescriptions 
recorded in hospitals, it is calculated that patients paid approximately 3 billion 
TL in total outpatient care as co-payment in 2012. cOnclusiOns: Minimum 9 
TL in total is required as a co-payment for outpatient care and prescription, if 
patient visits a public hospital. Therefore, for products with a lower price than 
10 TL, patients rather go directly to pharmacies. This behavioral change of out-
of-pocket payments might be explained by improved purchasing power and 
increased co-pay rates.
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Objectives: Decision making about health technologies from research and 
development to reimbursement is affected by heterogeneous opinion and cri-
teria of participating stakeholders. There is a lack of systematic consideration 
of stakeholders’ preferences in current health policy. Multi-criteria decision 
analysis (MCDA) offers a solution to take preferences into account. This study 
gives an overview about the applications of MCDA methods in health economic 
decision-making. MethOds: A systematic review of the health care literature 
was performed to identify original research articles. Using predefined categories, 
data was systematically extracted for the type of policy applications, MCDA 
methodology, criteria used and how they were defined. Results: Twenty-one 
studies were included in the analysis. 12 studies (67%) used indirect approaches 
and nine studies (43%) used direct MCDA approaches. Four studies (19%) focused 
on technologies in the early innovation process. The majority of 17 studies (81%) 
examined a technology on the level of reimbursement decision. Eight studies 
(38%) resulted into implementation, which means that an official committee 
considered the MCDA results. Other studies were conducted in an explorative 
manner. MCDA decision criteria used were obtained from literature research and 
context-specific studies, expert opinions, and group discussions. The number of 
criteria ranged from three up to 15. The most prominent criteria described health 
outcomes (71%), disease impact (62%), and implementation of the intervention 
(38%). cOnclusiOns: MCDA is used at different levels of medical innovation 
and can increase transparency for involved stakeholders by explicitly structuring 
decision criteria. Further research is needed to understand existing variability 
of the number of criteria used and ensure that models are robust regarding 
potential criteria overlaps, performance scales and operationalizability aligned 
with evidence needs.
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Objectives: In Turkey, almost everyone is covered by General Health Insurance 
Scheme (GHIS) under Social Security Institution (SSI). GHIS provides a Basic 
Benefit Package (BBP) for patients to benefit from both public and private health 
care providers contracted with SSI. Patients are obliged to pay certain level co-
pays for extra services as defined in the regulation. Besides GHIS, patients could 
benefit from private health insurances(PHI) by paying relatively high level of pre-
miums for different types of PHI packages. Supplementary Health Insurance(SHI) 
law has been enacted in June 2012 and patients started to benefit from SHI by 
paying relatively lower premiums for health care services that are not covered 
or partially covered by BBP. The objective is to evaluate the significance and 
potential of SHI in Turkey. MethOds: Regulations of SSI, OECD publications, 
International Investors Association’s Turkey Report and database of Insurance 
Association of Turkey are examined. Results: Number of private hospitals has 
increased by 50% over 5 years and reached out 500 by 2012. Parallel with this 
growth, PHI sector market share has also increased. By 2012, number of people 
covered by PHI has reached out more than 2 million and the PHI market is 
expected to reach nearly USD 2 billion in 2015. Meanwhile, approximately 20 
thousand people has covered by SHI since November 2012 and SHI is expected to 
reach 5 million people next 5 years. cOnclusiOns: Public health care expendi-
ture is continuously rising due to increased health demand, increased coverage 
and demographic changes. In order to assure a financially sustainable health 
care system, PHI could be an option and create source of funding for the health 
care expenditure. In this context, SHI will reduce the pressure on public health 
budget, create an area of growth for the private health insurance sector, allowing 
health care providers supplying both public and private health care to become 
more effective.
